Immuno-oncology combinations: a review of clinical experience and future prospects.

@article{Antonia2014ImmunooncologyCA,
  title={Immuno-oncology combinations: a review of clinical experience and future prospects.},
  author={Scott J. Antonia and James Larkin and Paolo Antonio Ascierto},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2014},
  volume={20 24},
  pages={6258-68}
}
Immuno-oncology is an evolving treatment modality that includes immunotherapies designed to harness the patient's own immune system. This approach is being studied for its potential to improve long-term survival across multiple tumor types. It is now important to determine how immunotherapies may be most effectively used to achieve the best possible patient outcomes. Combining or sequencing immunotherapies that target distinct immune pathways is a logical approach, with the potential to further… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 83 references

With the checkpoint inhibitors, can we call checkmate for cancer? [video on the Internet

WJ Urba
Alexandria (VA): American Society of Clinical Oncology; 2013 [cited 2014 Jul 2] • 2014
View 9 Excerpts
Highly Influenced

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2015
View 2 Excerpts

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2014
View 1 Excerpt

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) withmelanoma (MEL)

A Ribas, FS Hodi, +3 authors JD Wolchok
J Clin Oncol 2014;32:5s, • 2014

Similar Papers

Loading similar papers…